+357 96 030922
info@marketpublishers.com

Global Multi-Cancer Diagnostic Tests Market Research Report 2025(Status and Outlook)

https://marketpublishers.com/r/G4C1A8E05F6FEN.html
Date: September 2025
Pages: 129
Price: US$ 2,800.00 (Single User License)
ID: G4C1A8E05F6FEN

Abstracts

Report Overview

The multi-cancer diagnostic test market is focused on the development of diagnostic solutions that can detect multiple types of cancers simultaneously through a single test. These tests generally work by analyzing biological samples such as blood, urine, or saliva to identify biomarkers associated with different cancer types. The key feature of these tests is their ability to offer non-invasive, early detection, which is crucial for improving patient outcomes. Liquid biopsies, gene panels, and other diagnostic tools are often employed to enhance the sensitivity and accuracy of these tests.

The global multi-cancer diagnostic test market was valued at approximately $ 1.18 billion in 2024, and it is expected to grow at a compound annual growth rate (CAGR) of 16.4% from 2024 to 2032. This growth is fueled by the rising demand for non-invasive diagnostic procedures, increasing prevalence of cancers globally, and advancements in genetic testing technologies. The market's expansion is also supported by continuous innovations in liquid biopsy technologies and the growing adoption of multi-cancer early detection programs across healthcare settings. By 2032, the market is projected to reach a value of $4.01 billion.
Key drivers contributing to market growth include the increasing incidence of cancer worldwide, particularly among aging populations, and the shift toward personalized medicine. In addition, the growing demand for early cancer detection and the potential to use multi-cancer tests to screen individuals for a range of cancers in a single procedure are expected to further stimulate market growth. For instance, liquid biopsy technologies, which detect circulating tumor DNA (ctDNA), are expected to become a prominent tool in both clinical and research settings. In 2024, liquid biopsy testing is anticipated to become a common practice in oncology, as it allows for less invasive

+357 96 030922
info@marketpublishers.com

sample collection and faster results, driving its market adoption.

Emerging trends within the multi-cancer diagnostic test market include the continued development of next-generation sequencing (NGS) technologies and artificial intelligence (AI) algorithms to enhance diagnostic accuracy. These technologies are allowing companies to identify a broader range of biomarkers from a smaller amount of biological sample. For example, companies like Illumina and Guardant Health are integrating AI with genomic sequencing to provide more precise and faster multi-cancer detection. In 2024, it is expected that multi-cancer diagnostic platforms will further reduce testing costs while increasing the detection capabilities for cancers that are difficult to identify using traditional methods.

However, the market faces several challenges, including regulatory hurdles and the need for substantial clinical validation to establish the reliability and accuracy of multi-cancer diagnostic tests. While these tests show promise, obtaining regulatory approval from authorities like the FDA and EMA remains a time-consuming and expensive process. In 2024, many tests are still in the experimental phase, and only a few have been granted regulatory clearance for widespread use. Additionally, the market must overcome reimbursement issues in certain regions, which can slow the adoption of these diagnostic tools.

The multi-cancer diagnostic test market is segmented into liquid biopsy, gene panel, and other categories. Liquid biopsy is the largest segment due to its non-invasive nature and its ability to detect a wide range of cancers through ctDNA or other biomarkers found in blood. Gene panels, including Laboratory Developed Tests (LDTs), are also gaining traction due to their ability to provide detailed genetic information that can be used to guide treatment decisions. Hospitals and diagnostic laboratories are the largest application segments, as they are primary users of diagnostic tests in clinical settings. However, growing interest from research organizations and public health entities is also contributing to the market's expansion.

Geographically, North America is expected to dominate the multi-cancer diagnostic test market due to the presence of key market players such as Illumina and Exact Sciences, as well as strong healthcare infrastructure and high adoption rates of advanced diagnostic technologies. The market in Europe is also expected to experience significant growth, driven by increasing government support for cancer screening programs and rising healthcare expenditure. In Asia-Pacific, the market is expected to grow rapidly due to improving healthcare access, growing awareness of cancer detection, and advancements in biotechnology. China and Japan are expected to be key contributors to the market in this region.

The competitive landscape is defined by several key players, including Illumina, Exact Sciences, Foundation Medicine, AnchorDx, Guardant Health, and Burning Rock Biotech, which are leveraging advanced technologies such as next-generation

+357 96 030922
info@marketpublishers.com

sequencing and liquid biopsy to strengthen their market positions. These companies are actively involved in strategic collaborations, mergers, and acquisitions to expand their product portfolios and gain access to new markets. For example, Guardant Health has partnered with several healthcare providers to integrate its multi-cancer detection tests into routine screening practices. The competitive strategies of these companies focus on enhancing product accuracy, reducing costs, and ensuring regulatory approvals, as well as improving patient access to testing services.
In terms of market positioning, Illumina, Guardant Health, and Foundation Medicine hold leading positions in the liquid biopsy and gene panel segments, primarily due to their technological advancements, extensive product portfolios, and robust partnerships with healthcare providers. These companies are expected to continue dominating the market through innovations in multi-cancer diagnostic platforms and their ability to address the growing demand for early detection in oncology. However, smaller players such as Micronoma and Freenome are emerging as potential competitors, leveraging AI and machine learning to offer more efficient and personalized diagnostic solutions.

This report offers a comprehensive and in-depth analysis of the global Multi-Cancer Diagnostic Tests market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Multi-Cancer Diagnostic Tests market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Multi-Cancer Diagnostic Tests market.

Global Multi-Cancer Diagnostic Tests Market: Market Segmentation Analysis

+357 96 030922
info@marketpublishers.com

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Illumina, Inc.
Exact Sciences Corp.
Foundation Medicine, Inc.
AnchorDx
Guardant Health
Burning Rock Biotech Ltd.
GENECAST
Beijing Lyman Juntai
Freenome Holdings, Inc.
Elypta AB
AnPac Bio-Medical Science Co., Ltd.
EarlyDiagnostics
Genecast Biotechnology Co., Ltd.
Guangzhou AnchorDx Medical Co., Ltd.
Micronoma, Inc.
Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.)
SeekIn Inc.
Singlera Genomics Inc.
Market Segmentation (by Type)
Liquid Biopsy
Gene Panel, LDT
Others
Market Segmentation (by Application)
Hospitals
Diagnostic Laboratories

+357 96 030922
info@marketpublishers.com

Others

Geographic Segmentation

North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Multi-Cancer Diagnostic Tests Market
Overview of the regional outlook of the Multi-Cancer Diagnostic Tests Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Multi-Cancer Diagnostic Tests Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the

+357 96 030922
info@marketpublishers.com

market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Multi-Cancer Diagnostic Tests, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

+357 96 030922
info@marketpublishers.com

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
This enables you to anticipate market changes to remain ahead of your competitors
You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
Provision of market value data for each segment and sub-segment
Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Includes in-depth analysis of the market from various perspectives through Porter?s five forces analysis
Provides insight into the market through Value Chain
Market dynamics scenario, along with growth opportunities of the market in the years to come
6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

+357 96 030922
info@marketpublishers.com

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

1.1 Market Definition and Statistical Scope of Multi-Cancer Diagnostic Tests
1.2 Key Market Segments
  1.2.1 Multi-Cancer Diagnostic Tests Segment by Type
  1.2.2 Multi-Cancer Diagnostic Tests Segment by Application
1.3 Methodology & Sources of Information
  1.3.1 Research Methodology
  1.3.2 Research Process
  1.3.3 Market Breakdown and Data Triangulation
  1.3.4 Base Year
  1.3.5 Report Assumptions & Caveats

2 MULTI-CANCER DIAGNOSTIC TESTS MARKET OVERVIEW

2.1 Global Market Overview
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region

3 MULTI-CANCER DIAGNOSTIC TESTS MARKET COMPETITIVE LANDSCAPE

3.1 Company Assessment Quadrant
3.2 Global Multi-Cancer Diagnostic Tests Product Life Cycle
3.3 Global Multi-Cancer Diagnostic Tests Revenue Market Share by Company (2020-2025)
3.4 Multi-Cancer Diagnostic Tests Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.5 Multi-Cancer Diagnostic Tests Company Headquarters, Area Served, Product Type
3.6 Multi-Cancer Diagnostic Tests Market Competitive Situation and Trends
  3.6.1 Multi-Cancer Diagnostic Tests Market Concentration Rate
  3.6.2 Global 5 and 10 Largest Multi-Cancer Diagnostic Tests Players Market Share by Revenue
  3.6.3 Mergers & Acquisitions, Expansion

4 MULTI-CANCER DIAGNOSTIC TESTS VALUE CHAIN ANALYSIS

4.1 Multi-Cancer Diagnostic Tests Value Chain Analysis

+357 96 030922
info@marketpublishers.com

4.2 Midstream Market Analysis
4.3 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF MULTI-CANCER DIAGNOSTIC TESTS MARKET

5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
  5.4.1 New Product Developments
  5.4.2 Mergers & Acquisitions
  5.4.3 Expansions
  5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
  5.5.1 Industry Policies Analysis
  5.5.2 Economic Environment Analysis
  5.5.3 Social Environment Analysis
  5.5.4 Technological Environment Analysis
5.6 Global Multi-Cancer Diagnostic Tests Market Porter's Five Forces Analysis

6 MULTI-CANCER DIAGNOSTIC TESTS MARKET SEGMENTATION BY TYPE

6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Multi-Cancer Diagnostic Tests Market Size Market Share by Type (2020-2025)
6.3 Global Multi-Cancer Diagnostic Tests Market Size Growth Rate by Type (2021-2025)

7 MULTI-CANCER DIAGNOSTIC TESTS MARKET SEGMENTATION BY APPLICATION

7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Multi-Cancer Diagnostic Tests Market Size (M USD) by Application (2020-2025)
7.3 Global Multi-Cancer Diagnostic Tests Sales Growth Rate by Application (2020-2025)

8 MULTI-CANCER DIAGNOSTIC TESTS MARKET SEGMENTATION BY REGION

+357 96 030922
info@marketpublishers.com

8.1 Global Multi-Cancer Diagnostic Tests Market Size by Region
8.1.1 Global Multi-Cancer Diagnostic Tests Market Size by Region
8.1.2 Global Multi-Cancer Diagnostic Tests Market Size Market Share by Region
8.2 North America
8.2.1 North America Multi-Cancer Diagnostic Tests Market Size by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Multi-Cancer Diagnostic Tests Market Size by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Spain
8.4 Asia Pacific
8.4.1 Asia Pacific Multi-Cancer Diagnostic Tests Market Size by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Multi-Cancer Diagnostic Tests Market Size by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Multi-Cancer Diagnostic Tests Market Size by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa

9 KEY COMPANIES PROFILE

9.1 Illumina, Inc.

+357 96 030922
info@marketpublishers.com

9.1.1 Illumina, Inc. Basic Information
9.1.2 Illumina, Inc. Multi-Cancer Diagnostic Tests Product Overview
9.1.3 Illumina, Inc. Multi-Cancer Diagnostic Tests Product Market Performance
9.1.4 Illumina, Inc. SWOT Analysis
9.1.5 Illumina, Inc. Business Overview
9.1.6 Illumina, Inc. Recent Developments
9.2 Exact Sciences Corp.
9.2.1 Exact Sciences Corp. Basic Information
9.2.2 Exact Sciences Corp. Multi-Cancer Diagnostic Tests Product Overview
9.2.3 Exact Sciences Corp. Multi-Cancer Diagnostic Tests Product Market Performance
9.2.4 Exact Sciences Corp. SWOT Analysis
9.2.5 Exact Sciences Corp. Business Overview
9.2.6 Exact Sciences Corp. Recent Developments
9.3 Foundation Medicine, Inc.
9.3.1 Foundation Medicine, Inc. Basic Information
9.3.2 Foundation Medicine, Inc. Multi-Cancer Diagnostic Tests Product Overview
9.3.3 Foundation Medicine, Inc. Multi-Cancer Diagnostic Tests Product Market Performance
9.3.4 Foundation Medicine, Inc. SWOT Analysis
9.3.5 Foundation Medicine, Inc. Business Overview
9.3.6 Foundation Medicine, Inc. Recent Developments
9.4 AnchorDx
9.4.1 AnchorDx Basic Information
9.4.2 AnchorDx Multi-Cancer Diagnostic Tests Product Overview
9.4.3 AnchorDx Multi-Cancer Diagnostic Tests Product Market Performance
9.4.4 AnchorDx Business Overview
9.4.5 AnchorDx Recent Developments
9.5 Guardant Health
9.5.1 Guardant Health Basic Information
9.5.2 Guardant Health Multi-Cancer Diagnostic Tests Product Overview
9.5.3 Guardant Health Multi-Cancer Diagnostic Tests Product Market Performance
9.5.4 Guardant Health Business Overview
9.5.5 Guardant Health Recent Developments
9.6 Burning Rock Biotech Ltd.
9.6.1 Burning Rock Biotech Ltd. Basic Information
9.6.2 Burning Rock Biotech Ltd. Multi-Cancer Diagnostic Tests Product Overview
9.6.3 Burning Rock Biotech Ltd. Multi-Cancer Diagnostic Tests Product Market Performance

+357 96 030922
info@marketpublishers.com

9.6.4 Burning Rock Biotech Ltd. Business Overview
9.6.5 Burning Rock Biotech Ltd. Recent Developments
9.7 GENECAST
9.7.1 GENECAST Basic Information
9.7.2 GENECAST Multi-Cancer Diagnostic Tests Product Overview
9.7.3 GENECAST Multi-Cancer Diagnostic Tests Product Market Performance
9.7.4 GENECAST Business Overview
9.7.5 GENECAST Recent Developments
9.8 Beijing Lyman Juntai
9.8.1 Beijing Lyman Juntai Basic Information
9.8.2 Beijing Lyman Juntai Multi-Cancer Diagnostic Tests Product Overview
9.8.3 Beijing Lyman Juntai Multi-Cancer Diagnostic Tests Product Market Performance
9.8.4 Beijing Lyman Juntai Business Overview
9.8.5 Beijing Lyman Juntai Recent Developments
9.9 Freenome Holdings, Inc.
9.9.1 Freenome Holdings, Inc. Basic Information
9.9.2 Freenome Holdings, Inc. Multi-Cancer Diagnostic Tests Product Overview
9.9.3 Freenome Holdings, Inc. Multi-Cancer Diagnostic Tests Product Market Performance
9.9.4 Freenome Holdings, Inc. Business Overview
9.9.5 Freenome Holdings, Inc. Recent Developments
9.10 Elypta AB
9.10.1 Elypta AB Basic Information
9.10.2 Elypta AB Multi-Cancer Diagnostic Tests Product Overview
9.10.3 Elypta AB Multi-Cancer Diagnostic Tests Product Market Performance
9.10.4 Elypta AB Business Overview
9.10.5 Elypta AB Recent Developments
9.11 AnPac Bio-Medical Science Co., Ltd.
9.11.1 AnPac Bio-Medical Science Co., Ltd. Basic Information
9.11.2 AnPac Bio-Medical Science Co., Ltd. Multi-Cancer Diagnostic Tests Product Overview
9.11.3 AnPac Bio-Medical Science Co., Ltd. Multi-Cancer Diagnostic Tests Product Market Performance
9.11.4 AnPac Bio-Medical Science Co., Ltd. Business Overview
9.11.5 AnPac Bio-Medical Science Co., Ltd. Recent Developments
9.12 EarlyDiagnostics
9.12.1 EarlyDiagnostics Basic Information
9.12.2 EarlyDiagnostics Multi-Cancer Diagnostic Tests Product Overview
9.12.3 EarlyDiagnostics Multi-Cancer Diagnostic Tests Product Market Performance

+357 96 030922
info@marketpublishers.com

9.12.4 EarlyDiagnostics Business Overview
9.12.5 EarlyDiagnostics Recent Developments
9.13 Genecast Biotechnology Co., Ltd.
9.13.1 Genecast Biotechnology Co., Ltd. Basic Information
9.13.2 Genecast Biotechnology Co., Ltd. Multi-Cancer Diagnostic Tests Product Overview
9.13.3 Genecast Biotechnology Co., Ltd. Multi-Cancer Diagnostic Tests Product Market Performance
9.13.4 Genecast Biotechnology Co., Ltd. Business Overview
9.13.5 Genecast Biotechnology Co., Ltd. Recent Developments
9.14 Guangzhou AnchorDx Medical Co., Ltd.
9.14.1 Guangzhou AnchorDx Medical Co., Ltd. Basic Information
9.14.2 Guangzhou AnchorDx Medical Co., Ltd. Multi-Cancer Diagnostic Tests Product Overview
9.14.3 Guangzhou AnchorDx Medical Co., Ltd. Multi-Cancer Diagnostic Tests Product Market Performance
9.14.4 Guangzhou AnchorDx Medical Co., Ltd. Business Overview
9.14.5 Guangzhou AnchorDx Medical Co., Ltd. Recent Developments
9.15 Micronoma, Inc.
9.15.1 Micronoma, Inc. Basic Information
9.15.2 Micronoma, Inc. Multi-Cancer Diagnostic Tests Product Overview
9.15.3 Micronoma, Inc. Multi-Cancer Diagnostic Tests Product Market Performance
9.15.4 Micronoma, Inc. Business Overview
9.15.5 Micronoma, Inc. Recent Developments
9.16 Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.)
9.16.1 Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Basic Information
9.16.2 Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Multi-Cancer Diagnostic Tests Product Overview
9.16.3 Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Multi-Cancer Diagnostic Tests Product Market Performance
9.16.4 Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Business Overview
9.16.5 Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Recent Developments
9.17 SeekIn Inc.
9.17.1 SeekIn Inc. Basic Information
9.17.2 SeekIn Inc. Multi-Cancer Diagnostic Tests Product Overview
9.17.3 SeekIn Inc. Multi-Cancer Diagnostic Tests Product Market Performance
9.17.4 SeekIn Inc. Business Overview
9.17.5 SeekIn Inc. Recent Developments
9.18 Singlera Genomics Inc.

+357 96 030922
info@marketpublishers.com

9.18.1 Singlera Genomics Inc. Basic Information
9.18.2 Singlera Genomics Inc. Multi-Cancer Diagnostic Tests Product Overview
9.18.3 Singlera Genomics Inc. Multi-Cancer Diagnostic Tests Product Market Performance
9.18.4 Singlera Genomics Inc. Business Overview
9.18.5 Singlera Genomics Inc. Recent Developments

10 MULTI-CANCER DIAGNOSTIC TESTS MARKET FORECAST BY REGION

10.1 Global Multi-Cancer Diagnostic Tests Market Size Forecast
10.2 Global Multi-Cancer Diagnostic Tests Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Multi-Cancer Diagnostic Tests Market Size Forecast by Country
10.2.3 Asia Pacific Multi-Cancer Diagnostic Tests Market Size Forecast by Region
10.2.4 South America Multi-Cancer Diagnostic Tests Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Sales of Multi-Cancer Diagnostic Tests by Country

11 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2033)

11.1 Global Multi-Cancer Diagnostic Tests Market Forecast by Type (2026-2033)
11.2 Global Multi-Cancer Diagnostic Tests Market Forecast by Application (2026-2033)

12 CONCLUSION AND KEY FINDINGS

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. Introduction of the Type
Table 2. Introduction of the Application
Table 3. Market Size (M USD) Segment Executive Summary
Table 4. Multi-Cancer Diagnostic Tests Market Size Comparison by Region (M USD)
Table 5. Global Multi-Cancer Diagnostic Tests Revenue (M USD) by Company (2020-2025)
Table 6. Global Multi-Cancer Diagnostic Tests Revenue Share by Company (2020-2025)
Table 7. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Multi-Cancer Diagnostic Tests as of 2024)
Table 8. Multi-Cancer Diagnostic Tests Company Headquarters and Area Served
Table 9. Company Multi-Cancer Diagnostic Tests Product Type
Table 10. Global Multi-Cancer Diagnostic Tests Company Market Concentration Ratio (CR5 and HHI)
Table 11. Mergers & Acquisitions, Expansion Plans
Table 12. Midstream Market Analysis
Table 13. Downstream Customer Analysis
Table 14. Key Development Trends
Table 15. Driving Factors
Table 16. Multi-Cancer Diagnostic Tests Market Challenges
Table 17. Goldman Sachs' forecast real GDP growth rate for 2024-2026
Table 18. S&P Global ' Forecast Real GDP Growth Rate For 2024-2027
Table 19. World Bank ' Forecast Real GDP Growth Rate For 2024-2026
Table 20. Global Multi-Cancer Diagnostic Tests Market Size by Type (M USD)
Table 21. Global Multi-Cancer Diagnostic Tests Market Size (M USD) by Type (2020-2025)
Table 22. Global Multi-Cancer Diagnostic Tests Market Size Share by Type (2020-2025)
Table 23. Global Multi-Cancer Diagnostic Tests Market Size Growth Rate by Type (2021-2025)
Table 24. Global Multi-Cancer Diagnostic Tests Market Size by Application
Table 25. Global Multi-Cancer Diagnostic Tests Market Size by Application (2020-2025) & (M USD)
Table 26. Global Multi-Cancer Diagnostic Tests Market Share by Application (2020-2025)

+357 96 030922
info@marketpublishers.com

Table 27. Global Multi-Cancer Diagnostic Tests Sales Growth Rate by Application (2020-2025)
Table 28. Global Multi-Cancer Diagnostic Tests Market Size by Region (2020-2025) & (M USD)
Table 29. Global Multi-Cancer Diagnostic Tests Market Size Market Share by Region (2020-2025)
Table 30. North America Multi-Cancer Diagnostic Tests Market Size by Country (2020-2025) & (M USD)
Table 31. Europe Multi-Cancer Diagnostic Tests Market Size by Country (2020-2025) & (M USD)
Table 32. Asia Pacific Multi-Cancer Diagnostic Tests Market Size by Region (2020-2025) & (M USD)
Table 33. South America Multi-Cancer Diagnostic Tests Market Size by Country (2020-2025) & (M USD)
Table 34. Middle East and Africa Multi-Cancer Diagnostic Tests Market Size by Region (2020-2025) & (M USD)
Table 35. Illumina, Inc. Basic Information
Table 36. Illumina, Inc. Multi-Cancer Diagnostic Tests Product Overview
Table 37. Illumina, Inc. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 38. Illumina, Inc. SWOT Analysis
Table 39. Illumina, Inc. Business Overview
Table 40. Illumina, Inc. Recent Developments
Table 41. Exact Sciences Corp. Basic Information
Table 42. Exact Sciences Corp. Multi-Cancer Diagnostic Tests Product Overview
Table 43. Exact Sciences Corp. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 44. Exact Sciences Corp. SWOT Analysis
Table 45. Exact Sciences Corp. Business Overview
Table 46. Exact Sciences Corp. Recent Developments
Table 47. Foundation Medicine, Inc. Basic Information
Table 48. Foundation Medicine, Inc. Multi-Cancer Diagnostic Tests Product Overview
Table 49. Foundation Medicine, Inc. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 50. Foundation Medicine, Inc. SWOT Analysis
Table 51. Foundation Medicine, Inc. Business Overview
Table 52. Foundation Medicine, Inc. Recent Developments
Table 53. AnchorDx Basic Information
Table 54. AnchorDx Multi-Cancer Diagnostic Tests Product Overview

+357 96 030922
info@marketpublishers.com

Table 55. AnchorDx Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 56. AnchorDx Business Overview
Table 57. AnchorDx Recent Developments
Table 58. Guardant Health Basic Information
Table 59. Guardant Health Multi-Cancer Diagnostic Tests Product Overview
Table 60. Guardant Health Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 61. Guardant Health Business Overview
Table 62. Guardant Health Recent Developments
Table 63. Burning Rock Biotech Ltd. Basic Information
Table 64. Burning Rock Biotech Ltd. Multi-Cancer Diagnostic Tests Product Overview
Table 65. Burning Rock Biotech Ltd. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 66. Burning Rock Biotech Ltd. Business Overview
Table 67. Burning Rock Biotech Ltd. Recent Developments
Table 68. GENECAST Basic Information
Table 69. GENECAST Multi-Cancer Diagnostic Tests Product Overview
Table 70. GENECAST Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 71. GENECAST Business Overview
Table 72. GENECAST Recent Developments
Table 73. Beijing Lyman Juntai Basic Information
Table 74. Beijing Lyman Juntai Multi-Cancer Diagnostic Tests Product Overview
Table 75. Beijing Lyman Juntai Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 76. Beijing Lyman Juntai Business Overview
Table 77. Beijing Lyman Juntai Recent Developments
Table 78. Freenome Holdings, Inc. Basic Information
Table 79. Freenome Holdings, Inc. Multi-Cancer Diagnostic Tests Product Overview
Table 80. Freenome Holdings, Inc. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 81. Freenome Holdings, Inc. Business Overview
Table 82. Freenome Holdings, Inc. Recent Developments
Table 83. Elypta AB Basic Information
Table 84. Elypta AB Multi-Cancer Diagnostic Tests Product Overview
Table 85. Elypta AB Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 86. Elypta AB Business Overview

+357 96 030922
info@marketpublishers.com

Table 87. Elypta AB Recent Developments
Table 88. AnPac Bio-Medical Science Co., Ltd. Basic Information
Table 89. AnPac Bio-Medical Science Co., Ltd. Multi-Cancer Diagnostic Tests Product Overview
Table 90. AnPac Bio-Medical Science Co., Ltd. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 91. AnPac Bio-Medical Science Co., Ltd. Business Overview
Table 92. AnPac Bio-Medical Science Co., Ltd. Recent Developments
Table 93. EarlyDiagnostics Basic Information
Table 94. EarlyDiagnostics Multi-Cancer Diagnostic Tests Product Overview
Table 95. EarlyDiagnostics Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 96. EarlyDiagnostics Business Overview
Table 97. EarlyDiagnostics Recent Developments
Table 98. Genecast Biotechnology Co., Ltd. Basic Information
Table 99. Genecast Biotechnology Co., Ltd. Multi-Cancer Diagnostic Tests Product Overview
Table 100. Genecast Biotechnology Co., Ltd. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 101. Genecast Biotechnology Co., Ltd. Business Overview
Table 102. Genecast Biotechnology Co., Ltd. Recent Developments
Table 103. Guangzhou AnchorDx Medical Co., Ltd. Basic Information
Table 104. Guangzhou AnchorDx Medical Co., Ltd. Multi-Cancer Diagnostic Tests Product Overview
Table 105. Guangzhou AnchorDx Medical Co., Ltd. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 106. Guangzhou AnchorDx Medical Co., Ltd. Business Overview
Table 107. Guangzhou AnchorDx Medical Co., Ltd. Recent Developments
Table 108. Micronoma, Inc. Basic Information
Table 109. Micronoma, Inc. Multi-Cancer Diagnostic Tests Product Overview
Table 110. Micronoma, Inc. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 111. Micronoma, Inc. Business Overview
Table 112. Micronoma, Inc. Recent Developments
Table 113. Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Basic Information
Table 114. Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Multi-Cancer Diagnostic Tests Product Overview
Table 115. Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)

+357 96 030922
info@marketpublishers.com

Table 116. Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Business Overview
Table 117. Roche Holdings, Inc. (FOUNDATION MEDICINE, INC.) Recent Developments
Table 118. SeekIn Inc. Basic Information
Table 119. SeekIn Inc. Multi-Cancer Diagnostic Tests Product Overview
Table 120. SeekIn Inc. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 121. SeekIn Inc. Business Overview
Table 122. SeekIn Inc. Recent Developments
Table 123. Singlera Genomics Inc. Basic Information
Table 124. Singlera Genomics Inc. Multi-Cancer Diagnostic Tests Product Overview
Table 125. Singlera Genomics Inc. Multi-Cancer Diagnostic Tests Revenue (M USD) and Gross Margin (2020-2025)
Table 126. Singlera Genomics Inc. Business Overview
Table 127. Singlera Genomics Inc. Recent Developments
Table 128. Global Multi-Cancer Diagnostic Tests Market Size Forecast by Region (2026-2033) & (M USD)
Table 129. North America Multi-Cancer Diagnostic Tests Market Size Forecast by Country (2026-2033) & (M USD)
Table 130. Europe Multi-Cancer Diagnostic Tests Market Size Forecast by Country (2026-2033) & (M USD)
Table 131. Asia Pacific Multi-Cancer Diagnostic Tests Market Size Forecast by Region (2026-2033) & (M USD)
Table 132. South America Multi-Cancer Diagnostic Tests Market Size Forecast by Country (2026-2033) & (M USD)
Table 133. Middle East and Africa Multi-Cancer Diagnostic Tests Market Size Forecast by Country (2026-2033) & (M USD)
Table 134. Global Multi-Cancer Diagnostic Tests Market Size Forecast by Type (2026-2033) & (M USD)
Table 135. Global Multi-Cancer Diagnostic Tests Market Size Forecast by Application (2026-2033) & (M USD)

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Industry Chain of Multi-Cancer Diagnostic Tests
Figure 2. Data Triangulation
Figure 3. Key Caveats
Figure 4. Global Multi-Cancer Diagnostic Tests Market Size (M USD), 2024-2033
Figure 5. Global Multi-Cancer Diagnostic Tests Market Size (M USD) (2020-2033)
Figure 6. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 7. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 8. Evaluation Matrix of Regional Market Development Potential
Figure 9. Multi-Cancer Diagnostic Tests Market Size by Country (M USD)
Figure 10. Company Assessment Quadrant
Figure 11. Global Multi-Cancer Diagnostic Tests Product Life Cycle
Figure 12. Global Multi-Cancer Diagnostic Tests Revenue Share by Company in 2024
Figure 13. Multi-Cancer Diagnostic Tests Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2024
Figure 14. The Global 5 and 10 Largest Players: Market Share by Multi-Cancer Diagnostic Tests Revenue in 2024
Figure 15. Value Chain Map of Multi-Cancer Diagnostic Tests
Figure 16. Global Multi-Cancer Diagnostic Tests Market PEST Analysis
Figure 17. Global Multi-Cancer Diagnostic Tests Market Porter's Five Forces Analysis
Figure 18. Evaluation Matrix of Segment Market Development Potential (Type)
Figure 19. Global Multi-Cancer Diagnostic Tests Market Share by Type
Figure 20. Market Size Share of Multi-Cancer Diagnostic Tests by Type (2020-2025)
Figure 21. Market Size Share of Multi-Cancer Diagnostic Tests by Type in 2024
Figure 22. Global Multi-Cancer Diagnostic Tests Market Size Growth Rate by Type (2021-2025)
Figure 23. Evaluation Matrix of Segment Market Development Potential (Application)
Figure 24. Global Multi-Cancer Diagnostic Tests Market Share by Application
Figure 25. Global Multi-Cancer Diagnostic Tests Market Share by Application (2020-2025)
Figure 26. Global Multi-Cancer Diagnostic Tests Market Share by Application in 2024
Figure 27. Global Multi-Cancer Diagnostic Tests Sales Growth Rate by Application (2020-2025)
Figure 28. Global Multi-Cancer Diagnostic Tests Market Size Market Share by Region (2020-2025)
Figure 29. North America Multi-Cancer Diagnostic Tests Market Size and Growth Rate

+357 96 030922
info@marketpublishers.com

(2020-2025) & (M USD)
Figure 30. North America Multi-Cancer Diagnostic Tests Market Size Market Share by Country in 2024
Figure 31. U.S. Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 32. Canada Multi-Cancer Diagnostic Tests Market Size (M USD) and Growth Rate (2020-2025)
Figure 33. Mexico Multi-Cancer Diagnostic Tests Market Size (M USD) and Growth Rate (2020-2025)
Figure 34. Europe Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 35. Europe Multi-Cancer Diagnostic Tests Market Share by Country in 2024
Figure 36. Germany Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 37. France Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 38. U.K. Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 39. Italy Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 40. Spain Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 41. Asia Pacific Multi-Cancer Diagnostic Tests Market Size and Growth Rate (M USD)
Figure 42. Asia Pacific Multi-Cancer Diagnostic Tests Market Size Market Share by Region in 2024
Figure 43. China Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 44. Japan Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 45. South Korea Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 46. India Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 47. Southeast Asia Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 48. South America Multi-Cancer Diagnostic Tests Market Size and Growth Rate (M USD)
Figure 49. South America Multi-Cancer Diagnostic Tests Market Size Market Share by

+357 96 030922
info@marketpublishers.com

Country in 2024
Figure 50. Brazil Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 51. Argentina Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 52. Columbia Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 53. Middle East and Africa Multi-Cancer Diagnostic Tests Market Size and Growth Rate (M USD)
Figure 54. Middle East and Africa Multi-Cancer Diagnostic Tests Market Size Market Share by Region in 2024
Figure 55. Saudi Arabia Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 56. UAE Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 57. Egypt Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 58. Nigeria Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 59. South Africa Multi-Cancer Diagnostic Tests Market Size and Growth Rate (2020-2025) & (M USD)
Figure 60. Global Multi-Cancer Diagnostic Tests Market Size Forecast (2020-2033) & (M USD)
Figure 61. Global Multi-Cancer Diagnostic Tests Market Share Forecast by Type (2026-2033)
Figure 62. Global Multi-Cancer Diagnostic Tests Market Share Forecast by Application (2026-2033)

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Multi-Cancer Diagnostic Tests Market Research Report 2025(Status and Outlook)
Product link: https://marketpublishers.com/r/G4C1A8E05F6FEN.html
Price: US$ 2,800.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G4C1A8E05F6FEN.html